Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.
about
Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancerTargeted Therapies in Triple-Negative Breast CancerThe impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewBevacizumab treatment for advanced breast cancerSystemic treatment strategies for triple-negative breast cancer.Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials.Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trialEffect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer.Bevacizumab and breast cancer: current therapeutic progress and future perspectivesThe sequence of drug administration influences the antitumor effects of bevacizumab and cyclophosphamide in a neuroblastoma model.Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications.Pancreatic cancer: pathobiology, treatment options, and drug delivery.The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.Immunological Approaches in the Treatment of Metastasized Breast CancerBevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.Successful use of bevacizumb and paclitaxel in a male breast cancer with liver metastases.Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab.A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Promising molecular targeted therapies in breast cancerMagnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.Bevacizumab in metastatic breast cancer: when may it be used?Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer.An audit strategy for progression-free survival.Targeting the tumor microenvironment: focus on angiogenesis.Use of bevacizumab as a first-line treatment for metastatic breast cancer.Current targeted therapies in breast cancer: clinical applications in the elderly woman.Bevacizumab in the treatment of metastatic breast cancer: friend or foe?Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcomaPresent status and problems on molecular targeted therapy of cancerAnalyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.US Food and Drug Administration approval overview in metastatic breast cancerRandomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesEfficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.Epigenetics as a therapeutic target in breast cancer.Scheduling of anticancer drugs: timing may be everything.
P2860
Q24202199-9F0259F7-8F08-41F0-8C3D-D317CE948DC5Q26777736-745676D2-9CFE-40D9-891A-4B700A2C0F4AQ26824086-7F314561-4E0A-484B-B887-B8AC3FF82071Q27027498-B2E9750A-F273-44EF-BEBF-53DAC6A9F144Q27691414-4C532DC3-5E5D-4A1D-AD73-5D72E455474EQ30248296-AB9D3CF9-7B2B-45F0-8D45-E2F60D90D816Q31050387-F11A15A3-4402-4F72-A572-AC75615AB30EQ31060162-AD522399-11B3-43AA-A4CD-3B3CC8D14C31Q33413742-36E137B7-87D9-476A-B279-DCB3233AB1C2Q33424102-74304767-FFEF-4E63-8EE6-99FC6425ACEDQ33640753-B7D72E13-5E53-47AC-B3C6-6510960E0B9CQ33693571-B5C94CA6-89E2-4673-B923-C5860287E957Q33710475-B6632E3E-17A9-41CA-8D5D-2D15250245DFQ33749460-FA8F9CC6-BDDB-4E7C-B8B0-4C7821EA9781Q34096063-B9D57AC6-C80F-4CB3-B544-E89EF42E849AQ34120237-2F0D5EE2-C550-4739-A059-D41A51EC491CQ34140043-25919D04-F3EB-46A9-A94C-A08C21E1F5A3Q34206792-C08DB469-97D1-4065-B8F3-4A8B8B3E54A4Q34415276-C2038758-94D2-459B-AA87-EF199F406D46Q34680316-1EE0D014-4D1B-4508-BE2B-0E594450ED37Q35001280-7E95CB89-EA5C-4E71-8CBE-2A19E2A96791Q35040295-EF9E548F-8533-44A9-ADD3-85CFA79D5E28Q35061280-B6B33709-E242-4482-813C-68EEAEF3519AQ35076351-1A370EDB-61E0-4012-A5EF-742430DC7191Q35095635-C1B8C2DA-A6B8-4378-AA2F-F64C90207950Q35177892-58E6F30B-288B-417E-A69B-FD17C244D219Q35184806-E34A6C36-7A7B-4F7F-8BF8-CF234990DC24Q35445151-BCCC6749-8EC3-4894-B18B-A232E98149B4Q35584741-72619DFB-79B8-4901-BBFE-5DD0289B89B9Q35696743-52D2A205-B658-4D7B-A724-410DA7FA3D9BQ35713658-1E9F3156-CBA5-4D87-A2AF-3E37546CA8DCQ35877737-1980A814-33BA-465E-8F47-67FE19952A37Q35894702-9801E804-E21E-4534-9E5A-10C17EA48CB4Q36058269-AF1A284C-0721-47C4-A975-ED198A420DD5Q36058291-ED76FDCB-3AAB-4C29-93E9-67B28D9FE999Q36174876-E414E8F1-3AA6-4527-9B81-742C4799D799Q36304316-23B46A21-9F5A-46BF-AD04-BA9F986993B6Q36423995-7ED55B43-4911-4004-8286-A4CCA70586DEQ36449057-FE0FF0DC-BEBC-46E9-B528-FE39BF32063CQ36556304-6ABFEAF4-8C9F-4CD9-AACD-2D1744AEBB08
P2860
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Independent review of E2100: a ...... with metastatic breast cancer.
@ast
Independent review of E2100: a ...... with metastatic breast cancer.
@en
Independent review of E2100: a ...... with metastatic breast cancer.
@nl
type
label
Independent review of E2100: a ...... with metastatic breast cancer.
@ast
Independent review of E2100: a ...... with metastatic breast cancer.
@en
Independent review of E2100: a ...... with metastatic breast cancer.
@nl
prefLabel
Independent review of E2100: a ...... with metastatic breast cancer.
@ast
Independent review of E2100: a ...... with metastatic breast cancer.
@en
Independent review of E2100: a ...... with metastatic breast cancer.
@nl
P2093
P2860
P356
P1476
Independent review of E2100: a ...... with metastatic breast cancer.
@en
P2093
Christopher Bowden
Kathy Miller
Robert Gray
Robert L Comis
Suman Bhattacharya
P2860
P304
P356
10.1200/JCO.2008.21.6630
P407
P577
2009-08-31T00:00:00Z